We not only validated that SHON nuclear expression in tumour cells was an accurate predictive biomarker for ERα+ patients who received tamoxifen, but also identified that SHON cytoplasmic expression in ERα− tumours was able to predict the response of a patient to anthracycline-based treatment. The gene discussed is HIP1; the disease is neoplasm.